StockData

Exelixis vs Moderna

EXEL and MRNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How EXEL and MRNA compare

Moderna is the larger company, worth 4.9 times as much as Exelixis ($82.6B against $16.7B).

Exelixis grew revenue faster over the last twelve months (9.1% versus −27.6% for Moderna).

Exelixis keeps more of each dollar of sales as profit, with a net margin of 35.5% compared with −141% at Moderna.

Exelixis scores higher on the StockData Score (18 against 5 for Moderna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricEXELMRNA
Size and price
Market cap$16.7B$82.6B
Share price$68.50$206.80
Change, 1 year64.5%735%
Change, 5 years302%−37.3%
Beta (5Y)0.32−0.29
Employees1,0774,700
StockData Score
Total score18 (better)5
Valuation score3 (better)0
Growth score3 (better)1
Performance score6 (better)1
Health score6 (better)3
Dividend score00
Valuation
P/E20.5×–
P/S6.7× (better)37.1×
P/B9.1× (better)12.2×
EV/EBITDA15.3×–
P/FCF14.4×–
PEG0.29–
FCF yield6.9% (better)−1.5%
Fair value$66.21$32.48
Margin of safety−3.5% (better)−537%
Growth
Revenue growth (TTM)9.1% (better)−27.6%
Revenue growth, 5Y average18.6%19.3% (better)
Net income growth (TTM)30.6%–
EPS growth (TTM)40.9%–
EPS growth, 5Y average51.4%–
Profitability
Gross margin96.3% (better)23.4%
Operating margin40.2% (better)−149%
Net margin35.5% (better)−141%
FCF margin46.5% (better)−55.8%
Return on equity44.3% (better)−39.0%
Return on invested capital75.0% (better)−80.9%
Financial health
Debt / equity0.000.09 (better)
Current ratio3.21 (better)2.29
Altman Z-score17.36 (better)12.01
Piotroski F-score7 (better)3
Dividends and buybacks
Buyback yield7.5%–
Shareholder yield7.5% (better)0.00%
Ownership
Held by institutions106%79.9%
Held by insiders9.0%5.6%
Insider net buying, 12 months−$31.8M (better)−$81.6M
Short interest, % of float11.5%8.8%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.